<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">NPJ Schizophr</journal-id>
<journal-id journal-id-type="iso-abbrev">NPJ Schizophr</journal-id>
<journal-title-group>
<journal-title>NPJ Schizophrenia</journal-title>
</journal-title-group>
<issn pub-type="epub">2334-265X</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29093492</article-id>
<article-id pub-id-type="pmc">5665946</article-id>
<article-id pub-id-type="publisher-id">36</article-id>
<article-id pub-id-type="doi">10.1038/s41537-017-0036-2</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The association between gene variants and longitudinal structural brain changes in psychosis: a systematic review of longitudinal neuroimaging genetics studies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Harari</surname>
<given-names>Julia H.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8538-3175</contrib-id>
<name>
<surname>Díaz-Caneja</surname>
<given-names>Covadonga M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Janssen</surname>
<given-names>Joost</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martínez</surname>
<given-names>Kenia</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Arias</surname>
<given-names>Bárbara</given-names>
</name>
<address>
<email>barbara.arias@ub.edu</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Arango</surname>
<given-names>Celso</given-names>
</name>
<address>
<email>carango@hggm.es</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label>Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), School of Medicine, Universidad Complutense, Madrid, Spain </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2167 3675</institution-id><institution-id institution-id-type="GRID">grid.14003.36</institution-id><institution>University of Wisconsin School of Medicine and Public Health, </institution></institution-wrap>Madison, WI USA </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000000090126352</institution-id><institution-id institution-id-type="GRID">grid.7692.a</institution-id><institution>Department of Psychiatry, </institution><institution>Brain Center Rudolf Magnus, University Medical Center Utrecht, </institution></institution-wrap>Utrecht, The Netherlands </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0247</institution-id><institution-id institution-id-type="GRID">grid.5841.8</institution-id><institution>Zoology and Biological Anthropology Unit. Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals. IBUB., </institution><institution>Faculty of Biology, Universitat de Barcelona, </institution></institution-wrap>Barcelona, Spain </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9314 1427</institution-id><institution-id institution-id-type="GRID">grid.413448.e</institution-id><institution>CIBERSAM (Centro de Investigación Biomédica en Red de Salud Mental), </institution><institution>Instituto de Salud Carlos III, </institution></institution-wrap>Madrid, Spain </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>1</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>3</volume>
<elocation-id>40</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>18</day>
<month>8</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>8</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Evidence suggests that genetic variation might influence structural brain alterations in psychotic disorders. Longitudinal genetic neuroimaging (G-NI) studies are designed to assess the association between genetic variants, disease progression and brain changes. There is a paucity of reviews of longitudinal G-NI studies in psychotic disorders. A systematic search of PubMed from inception until November 2016 was conducted to identify longitudinal G-NI studies examining the link between Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI)-based brain measurements and specific gene variants (SNPs, microsatellites, haplotypes) in patients with psychosis. Eleven studies examined seven genes: BDNF, COMT, NRG1, DISC1, CNR1, GAD1, and G72. Eight of these studies reported at least one association between a specific gene variant and longitudinal structural brain changes. Genetic variants associated with longitudinal brain volume or cortical thickness loss included a 4-marker haplotype in G72, a microsatellite and a SNP in NRG1, and individual SNPs in DISC1, CNR1, BDNF, COMT and GAD1. Associations between genotype and progressive brain changes were most frequently observed in frontal regions, with five studies reporting significant interactions. Effect sizes for significant associations were generally of small or intermediate magnitude (Cohen’s <italic>d</italic> &lt; 0.8). Only two genes (BDNF and NRG1) were assessed in more than one study, with great heterogeneity of the results. Replication studies and studies exploring additional genetic variants identified by large-scale genetic analysis are warranted to further ascertain the role of genetic variants in longitudinal brain changes in psychosis.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p id="Par2">Psychotic disorders comprise a subset of psychiatric illnesses associated with severe consequences for affected individuals and a high global burden of disease.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> In these illnesses, genetic and environmental risk factors may interact with each other and with age-dependent neurodevelopmental processes to affect illness pathology and prognosis.<sup><xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR4">4</xref></sup> Longitudinal studies are particularly important as they allow for probing the interaction between risk factors and brain changes. Meta-analyses and reviews of longitudinal studies in adult-onset schizophrenia samples have demonstrated a great variability in results, even between studies using cohorts with similar characteristics.<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup> The most consistent results across studies are a progressive decline in cortical gray matter (GM) volume and progressive increases in lateral ventricle (LV) volume in patients when compared to healthy controls.<sup><xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR8">8</xref></sup> Similarly, a recent meta-analysis of early-onset psychosis (EOP, first appearance of psychotic symptoms before the age of 18 years) reported a significant progressive decrease in frontal GM volume in patients compared to controls during the first years following onset of psychotic symptoms.<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> However, results between individual EOP studies are heterogeneous,<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup> and some studies of psychotic cohorts report no progressive structural changes compared to healthy controls.<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>
</p>
<p id="Par3">The striking disparities between published results of longitudinal neuroimaging (NI) studies may be partially explained by the effect of genetic variation on brain changes. Schizophrenia (SCZ) demonstrates high heritability,<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup> with a significant portion of heritability attributable to the cumulative effect of many single nucleotide polymorphisms (SNPs).<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> Indeed, genetic association studies (including studies of previously-specified candidate SNPs, genome-wide association studies [GWAS], and studies using polygenic scores) have begun to identify SNPs in candidate genes that may contribute to the risk of developing a psychotic disorder.<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>
</p>
<p id="Par4">Genetic Neuroimaging (G-NI) studies analyze genetic variants and brain imaging measures in the same cohort, allowing for the assessment of associations between geno- and phenotype.<sup><xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR20">20</xref></sup> Large-scale analyses by collaborative consortiums such as Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) have suggested that genetic variation may impact structural measures such as intracranial volume (ICV) and various subcortical volumes across healthy and patient cohorts.<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup> In patients with psychotic disorders, genetic variants in certain genes (BDNF, COMT, RSG4, and ZNF804A, among several others) have been associated with average differences in GM and white matter (WM) brain volume, ventricular volume, and cortical thickness and folding patterns between patient genotype groups or patient vs. control genotype groups.<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup> However, the majority of published G-NI studies employed a cross-sectional design, which excludes the possibility of evaluating potential interactions between genetic measures and structural brain changes over time. This limitation precludes any conclusion about whether and which gene variants are associated with atypical brain changes in individuals with psychotic disorders.</p>
<p id="Par5">Previous reviews of G-NI studies in psychosis have either covered SNPs and neuroimaging in cross-sectional studies with no or only a few longitudinal studies mentioned;<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR29">29</xref></sup> have limited the scope to one or two candidate genes;<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup> or have geared the focus toward the description and use of specific neuroimaging methods rather than the integration and analysis of study results.<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup> Since characterizing whether and which genetic variants contribute to structural brain changes in psychosis is deemed highly relevant to the overall understanding of the disease, and many future studies will likely employ a longitudinal design, a review of longitudinal G-NI studies to date is warranted. Therefore, a systematic review was performed with the goal of synthesizing current knowledge of the association between genetic variants and progressive brain changes in psychotic disorders.</p>
</sec>
<sec id="Sec2" sec-type="results">
<title>Results</title>
<sec id="Sec3">
<title>Subject characteristics</title>
<p id="Par6">Of the eleven studies selected for review, five studies were conducted specifically in patients experiencing a first episode of psychosis (FEP).<sup><xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR38">38</xref></sup> Three studies evaluated patients with childhood-onset schizophrenia (COS).<sup><xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref></sup> Two studies were conducted in patients with recent-onset schizophrenia spectrum disorders (recent-onset SSD) (duration of illness &lt; 5 years), of which the percentage of FEP patients was not specified.<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup>
</p>
<p id="Par7">Patient cohort size at baseline ranged from 58 to 119 participants. Gender distribution ranged from 58 to 79% male, and mean AAO from 10 to 30.6 years old. Eight of the eleven studies included a healthy control (HC) group for genetic,<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup> structural MRI, or both types of analysis,<sup><xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup> and one of these studies also included a sibling comparison group.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>
</p>
<p id="Par8">Treatment with antipsychotic (AP) medication was described in eight studies.<sup><xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR44">44</xref></sup> Ethnic distribution of the samples was either all Caucasian,<sup><xref ref-type="bibr" rid="CR35">35</xref>–<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup> 95% Caucasian,<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup> or 50–72% Caucasian with the remaining portion accounted for by African American, Hispanic, and Asian participants, and participants of mixed ethnicities.<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref></sup> Additional details regarding clinical characteristics of the study samples can be found in Supplementary Table <xref ref-type="media" rid="MOESM1">1</xref>.</p>
</sec>
<sec id="Sec4">
<title>Genetic measures</title>
<p id="Par9">Genes examined were BDNF,<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup> COMT,<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> NRG1,<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup> DISC1,<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> CNR1,<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> GAD1,<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> and G72.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> All studies genotyped individual SNPs, three studies additionally performed haplotype analysis,<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup> and one study analyzed a microsatellite.<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> Information about genes, specific variants, and descriptions of function can be found in Table <xref ref-type="table" rid="Tab1">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Genes and specific variants assessed in the genetic neuroimaging studies included in the review</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Chromosome</th><th>Protein</th><th>Function</th><th>Polymorphisms included in this review</th><th>SNP Location</th><th>Functional consequences of the SNP</th><th>References</th></tr></thead><tbody><tr><td>
<italic>BDNF</italic>
</td><td>11p13</td><td>Brain derived neurotrophic factor</td><td>Neurotrophin that plays a role in neurodevelopmental processes, synaptic and cognitive plasticity, and neurotransmission</td><td>Val66Met (rs6265)</td><td>Exon 2</td><td>Met allele associated with impaired secretion and lower distribution of BDNF protein in neurons</td><td>Buckley et al.;<sup><xref ref-type="bibr" rid="CR71">71</xref></sup> Chen et al.;<sup><xref ref-type="bibr" rid="CR72">72</xref></sup> Egan et al.<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>
</td></tr><tr><td>
<italic>NRG1</italic>
</td><td>8p12-21</td><td>Neuregulin 1</td><td>Mediates cell-cell signaling, plays a role in neural development, neurotransmission and synaptic plasticity</td><td>SNP8NRG221533 (rs35753505)</td><td>Intronic, 5’ flanking region</td><td>Unknown</td><td>Harrison and Weinberger;<sup><xref ref-type="bibr" rid="CR74">74</xref></sup> Stefansson et al.<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>
</td></tr><tr><td></td><td></td><td></td><td></td><td>Microsatellite: 420M9-1395</td><td>5’ region</td><td>Unknown</td><td></td></tr><tr><td>
<italic>DISC1</italic>
</td><td>1q42.1</td><td>Disrupted in schizophrenia 1</td><td>Neurodevelopment and synaptic regulation</td><td>Leu607Phe (rs6675281)</td><td>Exon 9</td><td>Allele Phe607 and Cys704 affect expression of alternative transcripts of DISC1 that are expressed in early human brain development</td><td>Hennah and Porteus;<sup><xref ref-type="bibr" rid="CR76">76</xref></sup> Nakata et al.<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>
</td></tr><tr><td></td><td></td><td></td><td></td><td>Cys704Ser (rs821616)</td><td>Exon 11</td><td></td><td></td></tr><tr><td>
<italic>CNR1</italic>
</td><td>6q14-15</td><td>Cannabinoid receptor 1</td><td>GPCR for cannabinoids, mediates cannabinoid-induced CNS effects by modulating synaptic function and neurotransmission</td><td>rs1049353</td><td>Exon 4</td><td>Unknown</td><td>Castillo;<sup><xref ref-type="bibr" rid="CR82">82</xref></sup> Parsons and Hurd<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>
</td></tr><tr><td></td><td></td><td></td><td></td><td>rs2023239</td><td>Intron 2</td><td>Unknown</td><td></td></tr><tr><td>
<italic>GAD1</italic>
</td><td>2q31.1</td><td>GAD67 (glutamic acid decarboxylase)</td><td>Enzyme that catalyzes GABA synthesis in inhibitory neurons</td><td>rs2270335</td><td>Intron 1</td><td>Unknown</td><td>Blum and Mann;<sup><xref ref-type="bibr" rid="CR78">78</xref></sup> Straub et al.<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>
</td></tr><tr><td></td><td></td><td></td><td></td><td>rs2241165</td><td>Intron 2</td><td>Unknown</td><td></td></tr><tr><td>
<italic>G72</italic>
</td><td>13q32-34</td><td>D-amino acid oxidase activator</td><td>May regulate glutamate neurotransmission through interaction with DAAO. One isoform may play a role in mitochondrial function</td><td>rs3916965</td><td>5’ region</td><td>NA (sample divided and analyzed by haplotype, not individual SNPs)</td><td>Chumakov et al.;<sup><xref ref-type="bibr" rid="CR80">80</xref></sup> Kvajo et al.<sup><xref ref-type="bibr" rid="CR81">81</xref></sup>
</td></tr><tr><td></td><td></td><td></td><td></td><td>rs3916967</td><td>5’ region</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>rs2391191 (Arg30Lys)</td><td>Exon 2</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>rs778294</td><td>Intron 3</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Hap 1: AGAG</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Hap 2: GAGG</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Hap 3: GAGA</td><td></td><td></td></tr><tr><td>
<italic>COMT</italic>
</td><td>22q11</td><td>Catechol-O-methyl transferase</td><td>Enzyme that plays a role in the breakdown of catecholamines, including dopamine</td><td>Val158Met (rs4680)</td><td>Exon 4</td><td>Met allele encodes a lower-activity COMT variant, leading to impaired dopamine catabolism</td><td>Chen et al.;<sup><xref ref-type="bibr" rid="CR72">72</xref></sup> Harrison and Weinberger<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>
</td></tr></tbody></table><table-wrap-foot><p>Only SNPs and haplotypes that demonstrated an association with structural brain changes in the studies included in the review are shown</p><p>
<italic>Arg</italic> arginine, <italic>CNS</italic> central nervous system, <italic>Cys</italic>cysteine, <italic>DAAO</italic> D-amino acid oxidase, <italic>Hap</italic> haplotype, <italic>Leu</italic> leucine, <italic>Lys</italic> lysine, <italic>Met</italic> methionine, <italic>Phe</italic> phenylalanine, <italic>Ser</italic> serine, <italic>NA</italic> not applicable, <italic>SNP</italic> single nucleotide polymorphism, <italic>Val</italic> valine</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec5">
<title>Neuroimaging measures</title>
<p id="Par10">No DTI studies fulfilled the complete criteria for inclusion in the review. The eleven studies identified by the search criteria used structural MRI to measure brain changes, and MRI assessments were performed on a 1.5T scanner in all studies. Further details regarding image processing software, types of sequence, slice thickness and voxel size in each study can be found in Supplementary Table <xref ref-type="media" rid="MOESM1">1</xref>. Eight of the studies exclusively measured volume changes, with outcomes across the studies including changes in total or regional GM or WM volume, total or regional cortical or subcortical volume (structures included the hippocampus, thalamus, caudate nucleus, and cerebellum), LV volume, and cerebrospinal fluid (CSF) volume.<sup><xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR44">44</xref></sup> Two studies measured cortical thickness (CT) changes,<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup> and one study measured volume, CT, and cortical surface area (CSA) changes.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>
</p>
</sec>
<sec id="Sec6">
<title>Quality assessment</title>
<p id="Par11">Quality analysis showed that the studies included in the review were of high (64%) or moderate-high (36%) quality. Ratings for individual checklist items according to each study can be found in Supplementary Table <xref ref-type="media" rid="MOESM2">2</xref>.</p>
</sec>
<sec id="Sec7">
<title>Genetic x structural MRI findings</title>
<p id="Par12">Table <xref ref-type="table" rid="Tab2">2</xref> shows the main genetic x structural MRI findings from the eleven longitudinal G-NI studies retrieved. Five studies compared longitudinal brain changes between genotype or haplotype subgroups of patients with psychosis,<sup><xref ref-type="bibr" rid="CR37">37</xref>–<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup> while six studies compared longitudinal brain changes between genotype or haplotype groups in both patient and HC groups.<sup><xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Main genetic neuroimaging findings</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Author, Year cohort</th><th>Gene and SNP examined</th><th>Diagnosis N</th><th>Number of scans Follow-up</th><th>Morphological longitudinal measurements</th><th>Combined genetic and longitudinal NI results</th><th>EES, [95% CI]</th></tr></thead><tbody><tr><td>Ho 2007<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> Iowa Longitudinal study of recent onset schizophrenia</td><td>BDNF rs6265 (Val66Met)</td><td>Recent-onset SSD <italic>N</italic> = 119 (74 Val/Val; 45 Met-carriers)</td><td>2 scans 3 (1.6) years)</td><td>Frontal GM volume</td><td>Met-carriers ↓ Val/Val n.s.</td><td>0.38, [0.01, 0.75])</td></tr><tr><td></td><td></td><td></td><td></td><td>Temporal GM volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Parietal GM volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Occipital GM volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>LV volume</td><td>Met-carriers ↑</td><td>0.51, [0.14, 0.89]</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Val/Val n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Sulcal CSF volume</td><td>Met-carriers ↑</td><td>0.48, [0.11, 0.86]</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Val/Val n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Sulcal frontal CSF volume</td><td>Met-carriers ↑</td><td> ≥ 0.49</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Val/Val n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Sulcal temporal CSF volume</td><td>Met-carriers ↑</td><td> ≥ 0.49</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Val/Val n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Sulcal parietal and occipital CSF volume</td><td>n.s.</td><td></td></tr><tr><td>Koolschijn 2010<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>
</td><td>BDNF rs6265 (Val66Met)</td><td>SSD <italic>N</italic> = 87 (<italic>N</italic> = 68 with two scans) (44 Val/Val; 24 Met-carriers) HC <italic>N</italic> = 90 (<italic>N</italic> = 84 with two scans) (55 Val/Val; 29 Met-carriers)</td><td>2 scans (mean: SSD = 4.9 (0.5) years; HC = 4.9 (0.3) years)</td><td>Hippocampal volume</td><td>n.s.</td><td></td></tr><tr><td>Smith 2012<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>
</td><td>BDNF rs6265 (Val66Met)</td><td>FEP <italic>N</italic> = 58 (<italic>N</italic> = 41 with two scans) (25 Val/Val, 16 Met-carriers) HC <italic>N</italic> = 39 (<italic>N</italic> = 23 with two scans) (11 Val/Val; 12 Met-carriers)</td><td>2 scans (mean: 46 weeks)</td><td>Total brain volume Hippocampal volume</td><td>n.s.n.s.</td><td></td></tr><tr><td>Suárez-Pinilla 2013<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> PAFIP</td><td>BDNF rs6265 (Val66Met)</td><td>Non-affective FEP <italic>N</italic> = 80 (60 Val/Val; 20 Met-carriers) HC <italic>N</italic> = 54 (45 Val/Val; 9 Met-carriers)</td><td>2 scans (3 years)</td><td>Total brain volume Total GM volume Total WM volume</td><td>n.s. n.s. n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>LV volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Total CSF volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Caudate nucleus volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Thalamus volume</td><td>n.s.</td><td></td></tr><tr><td>Addington 2007<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> NIMH</td><td>NRG1 56 NRG1 markers: - 54 SNPs, 2 microsatellites - 2 erbB4 SNPs (genetic analysis only) Risk allele carriers: possession of microsatellite 420M9-1395</td><td>COS (onset before age 12) <italic>N</italic> = 59<sup>a</sup> (75% with ≥ 2 scans) (35 risk allele carriers; 24 no risk) HC <italic>N</italic> = 165<sup>a</sup> (65% with ≥ 2 scans) (131 risk allele carriers; 34 no risk allele)</td><td>Variable (approximately 2 years)</td><td>Total GM volumeFrontal GM volume</td><td>Greater ↓ in COS risk allele carriers than COS non-carriersn.s.</td><td>0.58 [0.05, 1.11]</td></tr><tr><td></td><td></td><td></td><td></td><td>Temporal GM volume</td><td>Greater ↓ in COS risk allele carriers than COS non-carriers</td><td>0.72 [0.18, 1.25]</td></tr><tr><td></td><td></td><td></td><td></td><td>Parietal GM volume</td><td>Greater ↓ in COS risk allele carriers than COS non-carriers</td><td>0.66 [0.13, 1.20]</td></tr><tr><td></td><td></td><td></td><td></td><td>Occipital GM volume</td><td>Greater ↓ in COS risk allele carriers than COS non-carriers</td><td>0.59 [0.06, 1.12]</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Greater ↓ in HC risk allele carriers than HC non-carriers</td><td>0.38 [0.001, 0.76]</td></tr><tr><td></td><td></td><td></td><td></td><td>Occipital WM volume</td><td>COS N.S. Greater ↓ in HC risk allele carriers than HC non-carriers</td><td>0.48 [0.10, 0.46]</td></tr><tr><td></td><td></td><td></td><td></td><td>Total WM volume, WM volumes of other lobes</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Caudate nucleus volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Cerebellum volume</td><td>n.s.</td><td></td></tr><tr><td>Suárez-Pinilla 2015<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> PAFIP</td><td>NRG1 a) SNP8NRG221132 (rs73235619) b) SNP8NRG221533 (rs35753505) c) SNP8NRG243177 (rs6994992)</td><td>Non-affective FEP<italic> N</italic> = 59 (31 SNP8NRG221533 C allele-carriers; 28 T/T) HC <italic>N</italic> = 14 (9 SNP8NRG221533 C allele-carriers; 5 T/T)</td><td>3 scans (1 year; 2 years)</td><td>Total brain volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Total GM volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Total WM volume</td><td>SNP8NRG6221533 C allele carriers: ↓ WM volume compared to T homozygotes at 3-year scan, but no significant genotype by time interaction.</td><td>0.55 [0.03, 1.07]</td></tr><tr><td></td><td></td><td></td><td></td><td>LV volume</td><td>SNP8NRG6221533 C allele carriers: 3-year ↑ compared to T homozygotes.</td><td>0.59 [0.07, 1.11]</td></tr><tr><td></td><td></td><td></td><td></td><td>Total CSF volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Caudate nucleus volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Thalamus volume</td><td>n.s.</td><td></td></tr><tr><td>Vázquez-Bourgon 2015<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> PAFIP</td><td>DISC1 (a) rs6675281 (Leu607Phe) (b) rs821616 (Ser704Cys)</td><td>Non-affective FEP <italic>N</italic> = 79 [<italic>N</italic> = 63 genotyped for rs6675281 (46 Leu/Leu; 17 Phe-carriers) and <italic>N</italic> = 60 genotyped for rs821616 (4 Ser/Ser; 56 Phe-carriers)]</td><td>2 scans (3 years)</td><td>Total CT Frontal CT</td><td>rs6675281: Phe-carriers ↑ Leu/Leu N.S.</td><td>0.84 [0.27, 1.42]</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>rs6675281 Phe + rs821616 Cys-carriers ↑</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>rs6675281 Phe-carriers ↑ Leu/Leu N.S.</td><td>0.79 [0.21, 1.36]</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>rs6675281 Phe + rs821616 Cys-carriers ↑</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Temporal CT</td><td>rs6675281 Leu/Leu ↓ rs6675281 Phe-carriers ↑</td><td>0.96 [0.38, 1.54]</td></tr><tr><td></td><td></td><td></td><td></td><td>Parietal CT</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Occipital CT</td><td>rs6675281 Phe + rs821616 Cys-carriers ↑</td><td></td></tr><tr><td>Suárez-Pinilla 2015<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> PAFIP</td><td>CNR1 (a) rs1049353 (b) rs1535255 (c) rs2023239</td><td>Non-affective FEP <italic>N</italic> = 65 (rs1049353: 36 G/G; 29 A-carriers rs2023239: 49 T/T; 16 T/C) HC <italic>N</italic> = 12 (genetic analysis only)</td><td>2 scans (3 years)</td><td>Total GM volume Total WM volume</td><td>n.s.n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>CSF volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>LV volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Thalamus volume</td><td>rs2023239: T/C patients ↓</td><td>0.59 [0.02, 1.16]</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>T/T patients ↓</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>T/C patients ↓ &gt;T/T patients</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Caudate nucleus volume</td><td>rs1049353: Both A-carrier and G/G reduction was N.S. A-carriers 3.27 times greater ↓ than G/G patients.</td><td>0.76 [0.26, 1.27]</td></tr><tr><td></td><td></td><td></td><td></td><td>CT</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Surface area</td><td>n.s.</td><td></td></tr><tr><td>Addington 2005<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> NIMH</td><td>GAD1 (a) 14 SNPs (b) one 4-marker combination</td><td>COS <italic>N</italic> = 72 (<italic>N </italic>= 39 with ≥ 2 scans)</td><td>2 scans (between 2 and 8 years)</td><td>Total GM volume</td><td>rs2270335 and rs2241165 were most strongly associated with progressive ↓</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Frontal GM volume</td><td>rs2270335 and rs2241165 were most strongly associated with progressive ↓</td><td></td></tr><tr><td>Hartz 2010<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> Iowa longitudinal study of recent onset psychoses</td><td>G72 4-marker combination: rs3916965, rs3916967, rs2391191, rs778294. Hap 1: AGAG Hap 2: GAGG Hap 3: GAGA</td><td>Recent-onset SSD <italic>N</italic> = 110 [(37/57/16) had (0/1/2) Hap 1 alleles; (60/41/9) had (0/1/2) Hap 3 alleles] HC <italic>N</italic> = 120 (genetic analysis only)</td><td>At least 2 scans (mean: 3.0 (1.6) years)</td><td>Total cerebral cortex volume</td><td>Hap 1 had a significant effect on volume change</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Total GM volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Total WM volume</td><td>Increased in Hap 3 homozygotes compared to other groups</td><td>1.31 [0.61, 2.01]</td></tr><tr><td></td><td></td><td></td><td></td><td>Total frontal lobe volume</td><td>Greater ↓ in Hap 1 homozygotes than other Hap 1 groups. N.S. changes in other Hap 1 groups.</td><td>0.84 [0.30, 1.39]</td></tr><tr><td></td><td></td><td></td><td></td><td>Frontal GM volume</td><td>Greater ↓ in Hap 1 homozygotes than other Hap 1 groups.</td><td>0.59 [0.06, 1.13]</td></tr><tr><td></td><td></td><td></td><td></td><td>Frontal WM volume</td><td>Greater ↓ in Hap 1 homozygotes than other Hap 1 groups.</td><td>0.54 [0.01, 1.08]</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Hap 3 had a significant effect on volume change.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Total parietal, temporal, occipital volume</td><td>n.s.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Parietal, temporal, and occipital WM volume</td><td>Hap 1 had a significant effect on occipital WM change. Hap 3 had an effect on change in parietal WM, temporal WM, and occipital WM. Significant ↑ in Hap 3 homozygotes compared to other Hap 3 groups in all three regions.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Parietal, temporal, and occipital GM volume</td><td>Hap 1 had an effect on parietal GM change.</td><td></td></tr><tr><td></td><td></td><td>COS (onset before age 13) <italic>N</italic> = 83 (<italic>N</italic> = 61 with ≥ 2 scans) (29 Val/Val, 42 Val/Met, 12 Met/Met)</td><td></td><td></td><td>
<italic>COS and SIB:</italic> Increased Val dose associated with accelerated CT thinning, particularly in fronto-temporal regions. HC: Increased Val dose associated with attenuation of CT loss in similar areas: bilateral PFC, temporal and superior parietal regions.</td><td></td></tr><tr><td>Raznahan 2011<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>NIMH</td><td>COMT Rs4680 (Val158Met)</td><td>SIB <italic>N</italic> = 62 (<italic>N </italic>= 33 with ≥ 2 scans) (19 Val/Val, 30 Val/Met, 13 Met/Met) HC <italic>N</italic> = 208 (<italic>N</italic> = 141 with ≥ 2 scans) (57 Val/Val, 91 Val/Met, 60 Met/Met)</td><td>Variable, (approximately 2 years)</td><td>Cortical thickness</td><td>
<italic>COS</italic> vs. <italic>HC:</italic> Significant differences in the relationship between Val dose and CT changes (i.e., accelerated thinning in COS and attenuated thinning in HC) were most prominent in left dlPFC and bilateral cingulate. Val dose-related CT decreases in dlPFC in COS compared to HC continued into adulthood.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>
<italic>SIB</italic> vs. <italic>HC:</italic> Significant differences in the relationship between Val dose and CT changes (i.e., accelerated thinning in SIB and attenuated thinning in HC) were most prominent in left IPS, bilateral IFG, AC and lateral temporal regions. Val-dose related CT decreases in SIB compared to HC resolved by age 20.</td><td></td></tr></tbody></table><table-wrap-foot><p>
<italic>AAO</italic> age at onset; <italic>AC</italic> anterior cingulate; <italic>COS</italic> childhood-onset schizophrenia; <italic>CSF</italic> cerebrospinal fluid; <italic>CT</italic> cortical thickness; <italic>dlPFC</italic> dorsolateral prefrontal cortex; <italic>EES</italic> estimated effect size, Cohen’s <italic>d</italic> with 95% confidence intervals calculated for significant findings based on data provided by the papers; <italic>FEP</italic> first-episode psychosis; <italic>GM</italic> gray matter; <italic>Hap</italic> haplotype, <italic>HC</italic> healthy controls; <italic>IFG</italic> inferior frontal gyrus; <italic>IPS</italic> intraparietal sulcus; <italic>LV</italic> lateral ventricles; <italic>NIMH</italic> National Institute of Mental Health; <italic>NR</italic> not reported; <italic>n.s.</italic>not significant; <italic>PAFIP</italic> Prospective Longitudinal Study on First-Episode Psychosis; <italic>PFC</italic> prefrontal cortex; <italic>SCZ</italic> schizophrenia; <italic>SIB</italic> siblings; <italic>SSD</italic> schizophrenia spectrum disorders (schizophrenia, schizophreniform disorder); <italic>TBV</italic> total brain volume; <italic>WM</italic> white matter.</p><p>
<sup>a</sup> For Addington et al.<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> sample size for longitudinal neuroimaging data was variable at each time point. EES were thus based on the numbers of patients in each genotype group with baseline neuroimaging data available</p></table-wrap-foot></table-wrap>
</p>
<sec id="Sec8">
<title>BDNF</title>
<p id="Par13">Out of four longitudinal G-NI studies evaluating BDNF, only one reported a significant association between BDNF variants and progressive brain changes. In an adult FEP sample, Met-carriers demonstrated significant progressive loss in frontal GM volume and progressive increase in LV and CSF volume over the three-year follow-up, while Val homozygotes did not show any significant changes during this period.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> No significant associations were observed between BDNF genotype and hippocampal volume change in either patients or HC in a FEP and HC study<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> and a SCZ and HC study,<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> or between BDNF genotype and changes in total brain volume (TBV), GM, WM, CSF, LV, thalamus and caudate nucleus volume in a FEP and HC study.<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>
</p>
</sec>
<sec id="Sec9">
<title>NRG1</title>
<p id="Par14">In an adult FEP sample, patient C allele carriers for SNP8NRG6221533 showed a significant increase in LV volume over 3 years compared to patient T homozygotes.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> Patient C allele carriers also showed decreased total WM volume compared to T homozygote patients at the 3-year time point, but the time x genotype interaction was not significant.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>
</p>
<p id="Par15">In a second NRG1 study, family-based transmission disequilibrium tests (TDT) showed that a microsatellite (420M9-1395) was strongly associated with COS.<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> COS risk allele carriers experienced a steeper rate of total GM volume loss into adolescence compared to COS non-carriers, a pattern observed throughout the temporal, parietal and occipital lobes. In the HC group, 420M9-1395 risk allele status affected GM and WM volume change in the occipital lobe only.</p>
</sec>
<sec id="Sec10">
<title>DISC1</title>
<p id="Par16">Of two DISC1 SNPs tested in a 3-year follow-up study of adult FEP patients, rs6675281 (Leu607Phe) was associated with longitudinal changes in total, frontal and temporal CT.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> While patients homozygous for the Leu allele showed a significant progressive CT decrease in temporal cortex, patient Phe allele carriers showed a progressive increase in total, frontal, and temporal CT. A significant association between rs6675281(Leu607Phe) and rs821616 (Ser704Cys) combined genotypes was also observed, with increases in total, frontal and occipital CT found only in Phe + Cys-carrier patients.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>
</p>
</sec>
<sec id="Sec11">
<title>CNR1</title>
<p id="Par17">Two of three CNR1 SNPs tested in a study in a FEP sample were associated with greater longitudinal decrease in volumes of subcortical structures.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> Caudate nucleus volume reductions over time were non-significant, but patient rs1049353 A-carriers demonstrated a 3.27 times greater decrease in caudate nucleus volume than G/G patients. For rs2023239, T/C patients showed a significantly greater longitudinal decrease in thalamic volume than T/T patients.</p>
</sec>
<sec id="Sec12">
<title>GAD1</title>
<p id="Par18">Family-based TDT in COS patients and their parents indicated a significant association between 3 GAD1 SNPs (rs3749034, rs2270335, rs2241165) and COS phenotype. Quantitative TDT (QTDT) showed that two of these SNPs (rs2270335, rs2241165) demonstrated the strongest associations with longitudinal total and frontal GM volume loss of the SNPs tested. For both SNPs, the common alleles over-represented in COS were also the ones associated with greater GM volume loss.<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>
</p>
</sec>
<sec id="Sec13">
<title>G72</title>
<p id="Par19">Of three four-marker haplotypes representing G72 SNPs rs3916965, rs3916967, rs2391191, and rs778294, homozygosity for haplotype 1 (AGAG) was associated with greater total frontal volume loss over 3 years when compared to other haplotype 1 groups in a sample of recent-onset SSD patients. Homozygosity for haplotype 3 (GAGA) was associated with progressive increases in subcortical white matter volume across all lobes compared to other haplotype 3 groups.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>
</p>
</sec>
<sec id="Sec14">
<title>COMT</title>
<p id="Par20">The COMT rs4680 (Val158Met) Val allele was over-represented in COS patients, and was associated with different patterns of CT development among COS, sibling (SIB), and HC comparison groups.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> Increased Val dose (having 2 vs. 1 vs. 0 Val alleles) was associated with an acceleration of cortical thinning in the COS and SIB group and an attenuation of CT loss in the HC group, particularly in fronto-temporal cortical regions. Differences were observed in the timing and regions most affected by Val dose in the COS and SIB groups (see Table <xref ref-type="table" rid="Tab2">2</xref>).</p>
</sec>
</sec>
<sec id="Sec15">
<title>Association of G-NI results with measures of clinical severity and cognitive functioning</title>
<p id="Par21">Three studies found an association between genetic variants linked with progressive brain changes and clinical or cognitive measures.<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup> In an adult recent-onset SSD sample, a four-marker G72 haplotype associated with increased frontal volume loss was also associated with greater severity of psychotic symptoms at follow-up (measured by the Scale for the Assessment of Positive Symptoms (SAPS) hallucinations and delusions domains).<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> In a CNR1 FEP sample, rs2023239 was associated both with the rate of thalamic volume reduction and with the amount of improvement observed in positive and negative symptomatology during follow-up.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> Specifically, rs2023239 T/C carriers showed greater progressive decreases in thalamic volume as well as less improvement in positive (SAPS) and negative (SANS) symptoms than their T/T counterparts. Finally, in a COS cohort, possession of an NRG1 microsatellite (420M9-1395) risk allele was associated with steeper rates of GM volume loss, and this same risk allele was also associated with poorer premorbid functioning (as measured by the Premorbid Adjustment Scale).<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>
</p>
</sec>
</sec>
<sec id="Sec16" sec-type="discussion">
<title>Discussion</title>
<p id="Par22">This is, to our knowledge, the first systematic review to explore the association between genetic variants and longitudinal structural brain changes in psychosis. Most of the genes yielding significant associations were evaluated in only one study (G72, DISC1, CNR1, GAD1, and COMT). Genes examined in more than one study were NRG1 and BDNF, and results from those studies were difficult to compare due to different genetic variants being tested (NRG1 studies) or considerable differences in demographic, clinical, and methodological variables (BDNF studies). A significant association between longitudinal volume or CT changes and specific genetic variants was most consistently reported in the frontal lobe, with five studies, out of seven specifically assessing this region, detecting a significant association. Results were mixed for the temporal, parietal and occipital lobes. This is consistent with meta-analyses usually reporting frontal regions as those showing the greatest longitudinal changes in studies measuring progressive brain changes in psychosis.<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup> Thus, the observation that genetic variants were primarily associated with changes in frontal regions may be linked with the increased vulnerability of this area to disease-associated longitudinal changes, particularly during the early phases of the illness and sensitive periods of neurodevelopment. Except for one study finding a significant association between polymorphisms in CNR1 and longitudinal changes in the caudate nucleus and thalamus, most of the studies assessing subcortical structures did not detect significant associations between genetic variants and changes in these regions. This is also consistent with meta-analyses of longitudinal brain changes in psychosis, which generally have not reported significant changes in subcortical structures over time,<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup> although one meta-analysis did report greater progressive decline in left caudate nucleus volume in SCZ patients compared to controls.<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> In the studies yielding significant associations between genetic variants and longitudinal changes, effect sizes were usually of small or intermediate magnitude,<sup><xref ref-type="bibr" rid="CR36">36</xref>–<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup> with large effects (Cohen’s <italic>d</italic> ≥ 0.8) only found for change in total WM and frontal lobe volume in the study assessing G72<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> and for change in total and temporal CT for the rs6675281 SNP in the study assessing DISC1.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> Since many genetic and environmental variables might impact deviant structural changes related to psychosis, it is to be expected that specific candidate genes may only account for very small amounts of variance in longitudinal brain changes seen in psychosis.</p>
<p id="Par23">The most frequently studied gene among studies identified by our search criteria was BDNF. Structural alterations associated with BDNF Val66Met genotype were frontal lobe GM, LV and sulcal CSF volume in one recent-onset SSD study,<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> but a separate study in non-affective FEP reported no interactions with these same regions despite similar cohort characteristics, length of follow-up, and image processing techniques.<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> A possible explanation for the differing results may be the younger age at onset and shorter duration of illness in the recent-onset SSD study. Another explanation could be potential differences in AP treatment status at baseline and during follow-up between the samples, as antipsychotics may have an effect on brain changes and different genetic backgrounds may interact with that effect.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>
</p>
<p id="Par24">The other gene examined in multiple longitudinal G-NI studies was NRG1, with results suggesting an effect for a 5’ SNP on LV changes in FEP patients and a 5’ microsatellite on the trajectory of brain changes in COS patients and controls.<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup> These two NRG1 studies and a COMT study were the only studies in this review to report that certain genetic variants were associated with greater progressive brain changes in patients but not in controls.<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup> These results suggest that certain genetic variants may have specific effects on progressive brain changes in psychosis. Another possibility is that certain variants have more marked effects on patients with psychosis, which make it easier to detect changes in these groups.</p>
<p id="Par25">In the COMT study, findings in COS and SIB groups were similar during adolescence, but by early adulthood Val dose-related CT differences between SIB and HC groups had disappeared while Val dose-related CT differences between COS and HC groups remained. This suggests that CT alterations associated with COMT genotype may exist on a continuum between psychotic patients, their siblings, and healthy controls, with brain changes at certain developmental stages only detectable in the psychotic sample. These results underscore the importance of including comparison groups in G-NI studies, as effects of genetic variants on structural patterns may differ between patients, relatives, and controls. Longitudinal comparison of these groups could help identify at-risk phenotypes in addition to characterizing actual disease progression.</p>
<p id="Par26">Along the lines of the COMT study, results from several other studies in this review suggest that the effect of certain genetic variants on brain changes might vary according to developmental stage or illness progression. NRG1 and DISC1 are highly relevant genes for neurodevelopmental and brain maturation processes. In the three studies examining these genes, cross-sectional results were either non-significant at some or all time points (as in the NRG1 FEP and DISC1 FEP studies),<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup> or only represented part of the developmental trajectory of volume changes (as in the NRG1 COS study).<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> The effect of a CNR1 SNP on caudate nucleus reduction rate was also undetectable at cross-sectional analysis. These findings suggest that certain genes may affect the progression or trajectory of structural brain changes during the early years of illness and support the use of a longitudinal design to appropriately assess their association.</p>
<p id="Par27">Three studies assessing genes involved in neurotransmission (GAD1, COMT, and G72) reported that genetic variants associated with progressive brain changes were also over-transmitted to patients or associated with the disease phenotype.<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup> Two 5’ GAD1 SNPs were associated with both COS and exaggerated cortical frontal GM loss.<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> The Val allele at COMT Val158Met was overrepresented in COS patients (but not in their siblings) compared to controls, and was associated with accelerated CT thinning in patients. A G72 haplotype associated with increased frontal volume loss in a recent- onset SSD cohort <sup><xref ref-type="bibr" rid="CR43">43</xref></sup> was consistent with alleles reported to be over-represented in SCZ cohorts in previous G72 genetic studies and meta-analyses.<sup><xref ref-type="bibr" rid="CR47">47</xref>–<xref ref-type="bibr" rid="CR49">49</xref></sup> This G72 haplotype was also associated with more severe psychotic symptoms at follow-up.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> Aside from G72, genetic variants in two other genes (NRG1 and CNR1) were also associated with both progressive brain changes and clinical measures. The association of the same genetic variants with progressive brain changes, increased disease risk, and/or clinical variables point to their potential role in the pathophysiology of schizophrenia and other psychoses, and to alterations in brain structure as a core component of the illness. Future studies should further explore the links between genetic variants, brain changes, and clinical progression. A better understanding of these relationships may eventually contribute to increased accuracy in predicting disease course and greater individualization of clinical care in patients with psychosis.</p>
<p id="Par28">Several limitations must be considered in interpreting the results of this review. First, the majority of the results have not been replicated, and since few studies evaluated a common genetic variant it was not possible to perform a quantitative synthesis and meta-analysis. Second, the overall number of studies included was low, all studies had relatively small sample sizes, and several of them were conducted by the same research groups. This means certain samples overlapped significantly and were comprised of participants from similar backgrounds that may not be representative of other populations. Considering studies carried out by different teams, several important factors such as cohort type, specific diagnosis, length of follow-up, ethnic composition, and genetic variant and NI measurement evaluated complicated direct comparison of results. Furthermore, besides those examining BDNF, almost every study reported a significant association between a genetic variant and progressive brain changes. This raises the question of whether associations with other brain regions may have been tested as well, but only positive associations were reported. Regarding the significance of findings, some of the studies did not provide sufficient information to calculate effect sizes and thereby quantify changes. Several of the studies did not include a healthy comparison group for NI changes. Another limitation was that cortical regions were assessed more often than subcortical regions during NI analysis, raising the possibility of region-reporting bias. Finally, most of the studies did not report on laterality when describing brain changes, making it difficult to determine whether changes were bilateral or whether any hemispheric differences were present.</p>
<p id="Par29">In the studies that yielded significant results, potential confounding factors must be considered. AP treatment may have an effect on certain brain volumes,<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> and these effects may differ depending on type (i.e., typical vs. atypical) of AP received.<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> Research has suggested AP treatment may not only influence brain structure independently but also interact with genes evaluated in these studies, with animal studies showing different effects for atypical and typical APs on BDNF levels and cell proliferation in the hippocampus.<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup> Participants received different AP medications in several studies included in this review, but not all controlled for AP treatment in statistical analysis. Several other environmental factors may have affected results through interactions with genes, brain structure, or both, such as childhood trauma, stress, and cannabis use.<sup><xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup> For example, studies in cohorts of patients with psychosis have indicated interactions between childhood trauma, BDNF expression or genotype, and hippocampal volumes.<sup><xref ref-type="bibr" rid="CR55">55</xref>–<xref ref-type="bibr" rid="CR57">57</xref></sup> The CNR1 study in this review reported interactions between CNR1 SNPs, and WM and LV volume changes in cannabis non-consumers, but not in cannabis consumers.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> Finally, given the limited variety of genes studied thus far, the lack of cohesive results may be partially due to the possibility that certain genetic variants relevant to progressive brain changes have not been studied yet. For example, genetic variants in genes related to inflammation and oxidative stress processes (such as genes involved in the synthesis and metabolism of glutathione, manganese superoxide dismutase, interleukins, major histocompatibility complex [MHC], or complement components) have increasingly been implicated in the pathophysiology of schizophrenia and other psychotic disorders,<sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref></sup> but are yet to be explored in a longitudinal G-NI study. Copy number variation (CNV) is another area that is yet to be extensively researched in relation to psychotic disorders. Certain copy number variants (such as 22q11.2 deletion, 16p11.2 duplication, and 3q29 deletion) have been implicated in the genetic architecture of psychotic disorders <sup><xref ref-type="bibr" rid="CR60">60</xref>–<xref ref-type="bibr" rid="CR62">62</xref></sup> and may be associated with structural brain differences in high-risk populations or patients with SCZ,<sup><xref ref-type="bibr" rid="CR63">63</xref>,<xref ref-type="bibr" rid="CR64">64</xref></sup> suggesting these variants may be promising avenues of investigation in longitudinal G-NI research.</p>
<p id="Par30">Candidate gene association studies in general are limited when used to address complex disorders and their associated outcomes, as significant associations are common but often fail to be replicated.<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> While the candidate gene approach has had some successes in identifying genetic variants associated with complex brain diseases—one example being the association between <italic>APOE</italic> variation and Alzheimer’s disease risk and brain structure<sup><xref ref-type="bibr" rid="CR66">66</xref>–<xref ref-type="bibr" rid="CR68">68</xref></sup>—similar results have not been achieved in schizophrenia, and recent research using GWAS and meta-analysis suggests that many historical candidate genes for schizophrenia (including BDNF, COMT, DISC1, and NRG1) fail to reach genome-wide significance.<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup> One promising approach to address the issue of low reproducibility of candidate gene association studies is conducting large scale meta-analysis via consortia such as ENIGMA, which will likely play an increasing role in the identification and replication of genetic variants relevant to brain changes and psychiatric illnesses.<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup> Thus far, large-scale genetic research in schizophrenia has pointed to the extended MHC and several genes involved in glutamatergic synaptic function and calcium signaling are important loci for future research, and has also highlighted the potential value of polygenic risk score analysis.<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup> Even with these advances, individual studies remain important since large-scale analysis is impossible without the contribution of individual datasets, and certain hypotheses and causal questions may be better addressed, at least initially, in smaller studies.<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>
</p>
<p id="Par31">Despite the mentioned limitations, this paper represents the first systematic review and qualitative analysis of studies of genetic variants and progressive structural brain changes in psychotic cohorts. Results from this review suggest that several genes related to neurodevelopment, brain maturation processes, neurotransmission and plasticity might impact progressive structural alterations in psychosis. However, sparse studies and discrepancies in cohort characteristics, genes and specific variants examined and study methodology make forming substantial conclusions difficult. In future studies, research groups should attempt to reproduce results in larger samples and different populations so that replicability is established. Researchers should pay particular attention to consistency of design, genes evaluated, and imaging parameters used, so that a more cohesive literature base addressing the role of these factors in psychosis can be developed. Furthermore, an effort should be made to include longitudinal clinical and cognitive measures in order to increase the applicability of genetic neuroimaging findings to other facets of psychotic illness.</p>
</sec>
<sec id="Sec17" sec-type="materials|methods">
<title>Methods</title>
<sec id="Sec18">
<title>Search strategy</title>
<p id="Par32">A systematic two-step literature search was performed according to the guidelines described in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement.<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> First, a PubMed database search from inception until November 2016 was performed with the following search terms: (gene OR SNP OR nucleotide OR polymorphism) AND (MRI OR “magnetic resonance imaging” OR neuroimaging OR cortical OR imaging OR DTI OR volume) AND (psychosis OR schizophrenia OR psychotic) AND (Humans[Mesh] AND English[lang]). Second, the reference lists of selected studies were manually reviewed to identify relevant studies missed by the initial computerized search. The original search yielded 1960 results, and five additional studies were identified during manual review.</p>
</sec>
<sec id="Sec19">
<title>Selection criteria</title>
<p id="Par33">1965 abstracts were assessed and considered for review if the study described met the following hierarchical eligibility criteria:<list list-type="order"><list-item><p id="Par34">The study was published as an original peer-reviewed article written in English.</p></list-item><list-item><p id="Par35">The study was performed in humans.</p></list-item><list-item><p id="Par36">The study included a patient group with a diagnosis of schizophrenia or other psychotic disorders according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria (DSM-III, DSM-III-R, DSM-IV, DSM-IV-TR, DSM-5).</p></list-item><list-item><p id="Par37">The study assessed both a genetic variant (SNP, microsatellite, or haplotype) and longitudinal changes in at least one structural and/or DTI-based MRI measure, including volume (total or regional cortical or subcortical brain volume, total or regional GM or WM volume, LV or cerebrospinal fluid [CSF] volume), cortical thickness (CT), cortical surface area (CSA), fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD).</p></list-item><list-item><p id="Par38">The study had a longitudinal design, with participants undergoing at least two structural MRI assessments over a period of time.</p></list-item></list>
</p>
<p id="Par39">The full text was consulted in cases where information provided by the abstract was not sufficient to evaluate eligibility or where no abstract was available. After full text review, a final group of eleven studies using T1 weighted images were included in the review. Figure <xref ref-type="fig" rid="Fig1">1</xref> provides a flowchart summarizing the selection process.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart of study selection. <italic>*</italic>Articles excluded for reasons not encompassed by other categories (<italic>N </italic>&lt; 5; results had not yet been reported; psychosis was induced by medication or another biological syndrome; the topic of the article was not relevant<italic>. SCZ s</italic>chizophrenia;<italic> MRI</italic> magnetic resonance imaging; <italic>DTI</italic> diffusion tensor imaging</p></caption><graphic id="d29e2765" xlink:href="41537_2017_36_Fig1_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec20">
<title>Data extraction, synthesis, and analysis</title>
<p id="Par40">Data for the following variables were retrieved for each study (see Supplementary Table <xref ref-type="media" rid="MOESM1">1</xref>): author names, year of publication, number of participants, diagnosis and diagnostic criteria, demographic variables (age at onset [AAO], age at baseline, duration of untreated illness [DUI], proportion of male subjects, medication, genetic data (gene and location; SNP, haplotype or microsatellite and location), structural neuroimaging data (number of scans, between-scan interval, structural brain measurements, software, scanner strength, type of T1-weighted sequence, slice thickness), genetic x neuroimaging outcome, and additional clinical or cognitive outcomes. Further information regarding genes and SNPs examined (i.e., function of gene, functional consequence of specific SNP) was collected from additional sources.<sup><xref ref-type="bibr" rid="CR71">71</xref>–<xref ref-type="bibr" rid="CR84">84</xref></sup> For the purpose of synthesis and analysis, studies were grouped by gene examined and thereafter by year of publication. For individual studies providing sample size and relevant statistics for significant genetic x neuroimaging findings, estimated effect sizes (Cohen’s <italic>d</italic>) with 95% confidence intervals were calculated using Comprehensive Meta-Analysis Software version 3 (Biostat, Inc., Englewood, NJ).</p>
</sec>
<sec id="Sec21">
<title>Quality assessment</title>
<p id="Par41">The quality of the studies was assessed using an item-checklist designed specifically for this review based on a previously published quality assessment of longitudinal neuroimaging studies in psychosis.<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> For each item, quality was assessed with a range of 0 (minimum) to 2 (maximum) points. The eleven studies were rated according to the sum of the points for each item, and then categorized as high (&gt;80% of the maximum possible points), moderate-high (60–79%), moderate (40–59%), moderate-low (20–39%), or low (&lt;19%) quality (see Supplementary Tables <xref ref-type="media" rid="MOESM2">2</xref> and <xref ref-type="media" rid="MOESM3">3</xref> for further details).</p>
</sec>
<sec id="Sec22">
<title>Data availability</title>
<p id="Par42">The authors declare that all data supporting the findings of this review are available within the paper and supplementary files.</p>
</sec>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic supplementary material</title>
<sec id="Sec23">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41537_2017_36_MOESM1_ESM.pdf"><caption><p>Supplementary Table 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41537_2017_36_MOESM2_ESM.pdf"><caption><p>Supplementary Table 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41537_2017_36_MOESM3_ESM.pdf"><caption><p>Supplementary Table 3</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Electronic supplementary material</bold>
</p>
<p>
<bold>Supplementary information</bold> accompanies the paper on the <italic>npj Schizophrenia</italic> website (10.1038/s41537-017-0036-2).</p>
</fn>
<fn>
<p>
<bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by the Spanish Ministry of Economy and Competitiveness. Instituto de Salud Carlos III, co-financed by ERDF Funds from the European Commission, “A way of making Europe” (PI12/01303, PI13/02112, PI4/00815), CIBERSAM. Madrid Regional Government (S2010/BMD-2422 AGES), European Union Structural Funds, European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMiSE), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY), and European Union H2020 Framework Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, project PRISM); Fundación Alicia Koplowitz and Fundación Mutua Madrileña. CD-C has previously held a grant from Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, and from Fundación Alicia Koplowitz. Thanks to FIS PI16/00998 and the Comissionat per a Universitat i Recerca del DIUE (2014SGR1636).</p>
</ack>
<notes notes-type="author-contribution">
<title>Author contributions</title>
<p>J.H. performed the literature review and extraction of data under the supervision of CD-C., J.H., CD-C., B.A., J.J., K.M., and C.A. contributed to the selection of variables of interest, the interpretation of findings, and the writing of the manuscript. All authors had full access to the data, take responsibility for their integrity and accuracy and approved the final version of the manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar1">
<title>Competing interests</title>
<p id="Par43">The authors declare that they have Competing financial interests.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<mixed-citation publication-type="other">Mathers, C., Fat, D. M., Boerma, J. T., &amp; World Health Organization. <italic>The global burden of disease: 2004 update</italic> (World Health Organization, 2008).</mixed-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woods</surname>
<given-names>BT</given-names>
</name>
</person-group>
<article-title>Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism</article-title>
<source/>Am. J. Psychiatr.
          <year>1998</year>
<volume>155</volume>
<fpage>1661</fpage>
<lpage>1670</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.155.12.1661</pub-id>
<pub-id pub-id-type="pmid">9842773</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGrath</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Feron</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Burne</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eyles</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>The neurodevelopmental hypothesis of schizophrenia: a review of recent developments</article-title>
<source/>Annu. Med.
          <year>2003</year>
<volume>35</volume>
<fpage>86</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1080/07853890310010005</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rapoport</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Giedd</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Gogtay</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Neurodevelopmental model of schizophrenia: update 2012</article-title>
<source/>Mol. Psychiatr.
          <year>2012</year>
<volume>17</volume>
<fpage>1228</fpage>
<lpage>1238</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2012.23</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olabi</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies</article-title>
<source/>Biol. Psychiatr.
          <year>2011</year>
<volume>70</volume>
<fpage>88</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2011.01.032</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vita</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Peri</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Deste</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sacchetti</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies</article-title>
<source/>Transl. psychiatr.
          <year>2012</year>
<volume>2</volume>
<fpage>e190</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2012.116</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kempton</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Stahl</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>DeLisi</surname>
<given-names>LE</given-names>
</name>
</person-group>
<article-title>Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies</article-title>
<source/>Schizophr. Res.
          <year>2010</year>
<volume>120</volume>
<fpage>54</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2010.03.036</pub-id>
<pub-id pub-id-type="pmid">20537866</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hulshoff Pol</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia</article-title>
<source/>Schizophr. Bull.
          <year>2008</year>
<volume>34</volume>
<fpage>354</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbm168</pub-id>
<pub-id pub-id-type="pmid">18283048</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraguas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Diaz-Caneja</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Pina-Camacho</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Arango</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Progressive brain changes in children and adolescents with early-onset psychosis: A meta-analysis of longitudinal MRI studies</article-title>
<source/>Schizophr. Res.
          <year>2016</year>
<volume>173</volume>
<fpage>132</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2014.12.022</pub-id>
<pub-id pub-id-type="pmid">25556081</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keller</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Corpus callosum development in childhood-onset schizophrenia</article-title>
<source/>Schizophr. Res.
          <year>2003</year>
<volume>62</volume>
<fpage>105</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/S0920-9964(02)00354-7</pub-id>
<pub-id pub-id-type="pmid">12765750</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>SL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Absence of anatomic corpus callosal abnormalities in childhood-onset schizophrenia patients and healthy siblings</article-title>
<source/>Psychiatry. Res.
          <year>2013</year>
<volume>211</volume>
<fpage>11</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.pscychresns.2012.09.013</pub-id>
<pub-id pub-id-type="pmid">23154096</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Javaloyes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>James</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Evidence for non-progressive changes in adolescent-onset schizophrenia: follow-up magnetic resonance imaging study</article-title>
<source/>Bri. J. Psychiatr.
          <year>2002</year>
<volume>180</volume>
<fpage>339</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.180.4.339</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haukvik</surname>
<given-names>UK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>No progressive brain changes during a 1-year follow-up of patients with first-episode psychosis</article-title>
<source/>Psychol. Med.
          <year>2016</year>
<volume>46</volume>
<fpage>589</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="doi">10.1017/S003329171500210X</pub-id>
<pub-id pub-id-type="pmid">26526001</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Kendler</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies</article-title>
<source/>Arch. Gen. Psychiatr.
          <year>2003</year>
<volume>60</volume>
<fpage>1187</fpage>
<lpage>1192</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.60.12.1187</pub-id>
<pub-id pub-id-type="pmid">14662550</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardno</surname>
<given-names>AG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heritability estimates for psychotic disorders: the Maudsley twin psychosis series</article-title>
<source/>Arch. Gen. Psychiatry.
          <year>1999</year>
<volume>56</volume>
<fpage>162</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.56.2.162</pub-id>
<pub-id pub-id-type="pmid">10025441</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<mixed-citation publication-type="other">Schizophrenia Working Group of the Psychiatric Genomics, C. Biological insights from 108 schizophrenia-associated genetic loci <italic>Nature</italic><bold>511</bold> 421–427 (2014).</mixed-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ripke</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide association analysis identifies 13 new risk loci for schizophrenia</article-title>
<source/>Nat. Genet.
          <year>2013</year>
<volume>45</volume>
<fpage>1150</fpage>
<lpage>1159</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2742</pub-id>
<pub-id pub-id-type="pmid">23974872</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer-Lindenberg</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Imaging genetics of schizophrenia</article-title>
<source/>Dialogues. Clin. Neurosci.
          <year>2010</year>
<volume>12</volume>
<fpage>449</fpage>
<lpage>456</lpage>
<pub-id pub-id-type="pmid">21319490</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging genetics and psychiatric disorders</article-title>
<source/>Curr. Mol. Med.
          <year>2015</year>
<volume>15</volume>
<fpage>168</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.2174/1566524015666150303104159</pub-id>
<pub-id pub-id-type="pmid">25732148</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hibar</surname>
<given-names>DP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common genetic variants influence human subcortical brain structures</article-title>
<source/>Nature
          <year>2015</year>
<volume>520</volume>
<fpage>224</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="doi">10.1038/nature14101</pub-id>
<pub-id pub-id-type="pmid">25607358</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>HH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel genetic loci underlying human intracranial volume identified through genome-wide association</article-title>
<source/>Nat. Neurosci.
          <year>2016</year>
<volume>19</volume>
<fpage>1569</fpage>
<lpage>1582</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4398</pub-id>
<pub-id pub-id-type="pmid">27694991</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gurung</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Prata</surname>
<given-names>DP</given-names>
</name>
</person-group>
<article-title>What is the impact of genome-wide supported risk variants for schizophrenia and bipolar disorder on brain structure and function? A systematic review</article-title>
<source/>Psychol. Med.
          <year>2015</year>
<volume>45</volume>
<fpage>2461</fpage>
<lpage>2480</lpage>
<pub-id pub-id-type="doi">10.1017/S0033291715000537</pub-id>
<pub-id pub-id-type="pmid">25858580</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Haren</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Genes and structural brain imaging in schizophrenia</article-title>
<source/>Curr. Opin. Psychiatry.
          <year>2008</year>
<volume>21</volume>
<fpage>161</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="doi">10.1097/YCO.0b013e3282f4f25b</pub-id>
<pub-id pub-id-type="pmid">18332664</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurnianingsih</surname>
<given-names>YA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder</article-title>
<source/>J. Neur. Trans.
          <year>2011</year>
<volume>118</volume>
<fpage>1621</fpage>
<lpage>1639</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-011-0672-z</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Najjar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pearlman</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Neuroinflammation and white matter pathology in schizophrenia: systematic review</article-title>
<source/>Schizophr. Res.
          <year>2015</year>
<volume>161</volume>
<fpage>102</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2014.04.041</pub-id>
<pub-id pub-id-type="pmid">24948485</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voineskos</surname>
<given-names>AN</given-names>
</name>
</person-group>
<article-title>Genetic underpinnings of white matter ‘connectivity’: heritability, risk, and heterogeneity in schizophrenia</article-title>
<source/>Schizophr. Res.
          <year>2015</year>
<volume>161</volume>
<fpage>50</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2014.03.034</pub-id>
<pub-id pub-id-type="pmid">24893906</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fineberg</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Ellman</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia</article-title>
<source/>Biol. Psychiatry.
          <year>2013</year>
<volume>73</volume>
<fpage>951</fpage>
<lpage>966</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.01.001</pub-id>
<pub-id pub-id-type="pmid">23414821</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenberg</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>KF</given-names>
</name>
</person-group>
<article-title>Executive function, neural circuitry, and genetic mechanisms in schizophrenia</article-title>
<source/>Neuropsychopharmacology
          <year>2010</year>
<volume>35</volume>
<fpage>258</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2009.111</pub-id>
<pub-id pub-id-type="pmid">19693005</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birur</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kraguljac</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>Shelton</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Lahti</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder—a systematic review of the magnetic resonance neuroimaging literature</article-title>
<source/>npj Schizophrenia
          <year>2017</year>
<volume>3</volume>
<fpage>15</fpage>
<pub-id pub-id-type="doi">10.1038/s41537-017-0013-9</pub-id>
<pub-id pub-id-type="pmid">28560261</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duff</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Macritchie</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Moorhead</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Lawrie</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Blackwood</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Human brain imaging studies of DISC1 in schizophrenia, bipolar disorder and depression: a systematic review</article-title>
<source/>Schizophr. Res.
          <year>2013</year>
<volume>147</volume>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2013.03.015</pub-id>
<pub-id pub-id-type="pmid">23602339</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Notaras</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van den Buuse</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2015</year>
<volume>51</volume>
<fpage>15</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.12.016</pub-id>
<pub-id pub-id-type="pmid">25562189</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roffman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Goff</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia</article-title>
<source/>Harv. Rev. Psychiatr.
          <year>2006</year>
<volume>14</volume>
<fpage>78</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1080/10673220600642945</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bearden</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>van Erp</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Toga</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>TD</given-names>
</name>
</person-group>
<article-title>Cortical mapping of genotype-phenotype relationships in schizophrenia</article-title>
<source/>Hum. Brain. Mapp.
          <year>2007</year>
<volume>28</volume>
<fpage>519</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="doi">10.1002/hbm.20404</pub-id>
<pub-id pub-id-type="pmid">17437284</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>GN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis</article-title>
<source/>Schizophr. Res.
          <year>2012</year>
<volume>134</volume>
<fpage>253</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2011.11.022</pub-id>
<pub-id pub-id-type="pmid">22192502</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suarez-Pinilla</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>BDNF Val66Met variants and brain volume changes in non-affective psychosis patients and healthy controls: a 3 year follow-up study</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatr.
          <year>2013</year>
<volume>45</volume>
<fpage>201</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.05.014</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suarez-Pinilla</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Progressive structural brain changes and NRG1 gene variants in first-episode nonaffective psychosis</article-title>
<source/>Neuropsychobiology
          <year>2015</year>
<volume>71</volume>
<fpage>103</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1159/000370075</pub-id>
<pub-id pub-id-type="pmid">25871612</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suarez-Pinilla</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms</article-title>
<source/>Psychiatry. Res.
          <year>2015</year>
<volume>233</volume>
<fpage>112</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1016/j.pscychresns.2015.05.005</pub-id>
<pub-id pub-id-type="pmid">26071625</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<mixed-citation publication-type="other">Vazquez-Bourgon, J. et al. Variations in disrupted-in-Schizophrenia 1 gene modulate long-term longitudinal differences in cortical thickness in patients with a first-episode of psychosis. <italic>Brain. Imaging. Behav.</italic>10.1007/s11682-015-9433-1 (2015).</mixed-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Addington</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss</article-title>
<source/>Mol. Psychiatr.
          <year>2005</year>
<volume>10</volume>
<fpage>581</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001599</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Addington</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuregulin 1 (8p12) and childhood-onset schizophrenia: susceptibility haplotypes for diagnosis and brain developmental trajectories</article-title>
<source/>Mol. Psychiatr.
          <year>2007</year>
<volume>12</volume>
<fpage>195</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001906</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raznahan</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Catechol-o-methyl transferase (COMT) val158met polymorphism and adolescent cortical development in patients with childhood-onset schizophrenia, their non-psychotic siblings, and healthy controls</article-title>
<source/>Neuroimage
          <year>2011</year>
<volume>57</volume>
<fpage>1517</fpage>
<lpage>1523</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.05.032</pub-id>
<pub-id pub-id-type="pmid">21620981</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Andreasen</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Wassink</surname>
<given-names>TH</given-names>
</name>
</person-group>
<article-title>Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia</article-title>
<source/>Am. J. Psychiatr.
          <year>2007</year>
<volume>164</volume>
<fpage>1890</fpage>
<lpage>1899</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2007.05111903</pub-id>
<pub-id pub-id-type="pmid">18056245</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hartz</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>G72 Influences longitudinal change in frontal lobe volume in schizophrenia</article-title>
<source/>Am. J. Med. Genet. Part B Neuropsychiatr. Genet.
          <year>2010</year>
<volume>153B</volume>
<fpage>640</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.31033</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koolschijn</surname>
<given-names>PC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia</article-title>
<source/>Hippocampus
          <year>2010</year>
<volume>20</volume>
<fpage>1010</fpage>
<lpage>1017</lpage>
<pub-id pub-id-type="doi">10.1002/hipo.20699</pub-id>
<pub-id pub-id-type="pmid">19714565</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fusar-Poli</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2013</year>
<volume>37</volume>
<fpage>1680</fpage>
<lpage>1691</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2013.06.001</pub-id>
<pub-id pub-id-type="pmid">23769814</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steen</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Mull</surname>
<given-names>C</given-names>
</name>
<name>
<surname>McClure</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hamer</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies</article-title>
<source/>Bri. J. Psychiatr.
          <year>2006</year>
<volume>188</volume>
<fpage>510</fpage>
<lpage>518</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.188.6.510</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Detera-Wadleigh</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>FJ</given-names>
</name>
</person-group>
<article-title>G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis</article-title>
<source/>Biol. Psychiatr.
          <year>2006</year>
<volume>60</volume>
<fpage>106</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2006.01.019</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yue</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of G72/G30 polymorphisms with early-onset and male schizophrenia</article-title>
<source/>Neuroreport
          <year>2006</year>
<volume>17</volume>
<fpage>1899</fpage>
<lpage>1902</lpage>
<pub-id pub-id-type="doi">10.1097/WNR.0b013e3280102ed4</pub-id>
<pub-id pub-id-type="pmid">17179866</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies</article-title>
<source/>Genetics
          <year>2007</year>
<volume>175</volume>
<fpage>917</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="doi">10.1534/genetics.106.061796</pub-id>
<pub-id pub-id-type="pmid">17179078</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieberman</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antipsychotic drug effects on brain morphology in first-episode psychosis</article-title>
<source/>Arch. Gen. Psychiatr.
          <year>2005</year>
<volume>62</volume>
<fpage>361</fpage>
<lpage>370</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.62.4.361</pub-id>
<pub-id pub-id-type="pmid">15809403</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parikh</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Mahadik</surname>
<given-names>SP</given-names>
</name>
</person-group>
<article-title>Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol</article-title>
<source/>Neurosci. Lett.
          <year>2004</year>
<volume>356</volume>
<fpage>135</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2003.10.079</pub-id>
<pub-id pub-id-type="pmid">14746882</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YH</given-names>
</name>
</person-group>
<article-title>Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats</article-title>
<source/>Neurosci. Lett.
          <year>2006</year>
<volume>402</volume>
<fpage>25</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2006.03.028</pub-id>
<pub-id pub-id-type="pmid">16713676</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holtzman</surname>
<given-names>CW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Stress and neurodevelopmental processes in the emergence of psychosis</article-title>
<source/>Neuroscience
          <year>2013</year>
<volume>249</volume>
<fpage>172</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.12.017</pub-id>
<pub-id pub-id-type="pmid">23298853</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habets</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Marcelis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gronenschild</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Drukker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Os</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia</article-title>
<source/>Biol. Psychiatr.
          <year>2011</year>
<volume>69</volume>
<fpage>487</fpage>
<lpage>494</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2010.08.010</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aas</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>BDNF val66met modulates the association between childhood trauma, cognitive and brain abnormalities in psychoses</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatr.
          <year>2013</year>
<volume>46</volume>
<fpage>181</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.07.008</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aas</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interplay between childhood trauma and BDNF val66met variants on blood BDNF mRNA levels and on hippocampus subfields volumes in schizophrenia spectrum and bipolar disorders</article-title>
<source/>J. Psychiatr. Res.
          <year>2014</year>
<volume>59</volume>
<fpage>14</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2014.08.011</pub-id>
<pub-id pub-id-type="pmid">25246365</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mondelli</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume</article-title>
<source/>J. Clin. Psychiatr.
          <year>2011</year>
<volume>72</volume>
<fpage>1677</fpage>
<lpage>1684</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.10m06745</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bitanihirwe</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>TU</given-names>
</name>
</person-group>
<article-title>Oxidative stress in schizophrenia: an integrated approach</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2011</year>
<volume>35</volume>
<fpage>878</fpage>
<lpage>893</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2010.10.008</pub-id>
<pub-id pub-id-type="pmid">20974172</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekar</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Schizophrenia risk from complex variation of complement component 4</article-title>
<source/>Nature
          <year>2016</year>
<volume>530</volume>
<fpage>177</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1038/nature16549</pub-id>
<pub-id pub-id-type="pmid">26814963</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rutkowski</surname>
<given-names>TP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Unraveling the genetic architecture of copy number variants associated with schizophrenia and other neuropsychiatric disorders</article-title>
<source/>J. Neurosci. Res.
          <year>2017</year>
<volume>95</volume>
<fpage>1144</fpage>
<lpage>1160</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.23970</pub-id>
<pub-id pub-id-type="pmid">27859486</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<mixed-citation publication-type="other">Cnv, Schizophrenia Working Groups of the Psychiatric Genomics, C. &amp; Psychosis Endophenotypes International, C. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects <italic>Nat. Genet.</italic><bold>49</bold> 27–35 (2017).</mixed-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rees</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Analysis of copy number variations at 15 schizophrenia-associated loci</article-title>
<source/>Br. J. Psychiatr.
          <year>2014</year>
<volume>204</volume>
<fpage>108</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.bp.113.131052</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maillard</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity</article-title>
<source/>Mol. Psychiatr.
          <year>2015</year>
<volume>20</volume>
<fpage>140</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2014.145</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Reutens</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mowry</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Copy number deletion burden is associated with cognitive, structural, and resting-state network differences in patients with schizophrenia</article-title>
<source/>Behav. Brain. Res.
          <year>2014</year>
<volume>272</volume>
<fpage>324</fpage>
<lpage>334</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2014.07.002</pub-id>
<pub-id pub-id-type="pmid">25036426</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arango</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Candidate gene associations studies in psychiatry: time to move forward</article-title>
<source/>Eur. Arch. Psychiatr. Clin. Neurosci.
          <year>2017</year>
<volume>267</volume>
<fpage>1</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="doi">10.1007/s00406-016-0765-7</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farrell</surname>
<given-names>MS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluating historical candidate genes for schizophrenia</article-title>
<source/>Mol. Psychiatr.
          <year>2015</year>
<volume>20</volume>
<fpage>555</fpage>
<lpage>562</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2015.16</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Clinical genetics of Alzheimer’s disease</article-title>
<source/>Biomed. Res. Int.
          <year>2014</year>
<volume>2014</volume>
<fpage>291862</fpage>
<pub-id pub-id-type="pmid">24955352</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roussotte</surname>
<given-names>FF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Combined effects of Alzheimer risk variants in the CLU and ApoE genes on ventricular expansion patterns in the elderly</article-title>
<source/>J. Neurosci.
          <year>2014</year>
<volume>34</volume>
<fpage>6537</fpage>
<lpage>6545</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5236-13.2014</pub-id>
<pub-id pub-id-type="pmid">24806679</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>PM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ENIGMA and the individual:predicting factors that affect the brain in 35 countries worldwide</article-title>
<source/>Neuroimage
          <year>2017</year>
<volume>145</volume>
<fpage>389</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2015.11.057</pub-id>
<pub-id pub-id-type="pmid">26658930</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moher</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liberati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tetzlaff</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>Preferred reporting items for systematic reviews and meta-analyzes: the PRISMA statement</article-title>
<source/>BMJ.
          <year>2009</year>
<volume>339</volume>
<fpage>b2535</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.b2535</pub-id>
<pub-id pub-id-type="pmid">19622551</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buckley</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Pillai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Howell</surname>
<given-names>KR</given-names>
</name>
</person-group>
<article-title>Brain-derived neurotrophic factor: findings in schizophrenia</article-title>
<source/>Curr. Opin. Psychiatr.
          <year>2011</year>
<volume>24</volume>
<fpage>122</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1097/YCO.0b013e3283436eb7</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>ZY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons</article-title>
<source/>J. Neurosci.
          <year>2004</year>
<volume>24</volume>
<fpage>4401</fpage>
<lpage>4411</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0348-04.2004</pub-id>
<pub-id pub-id-type="pmid">15128854</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egan</surname>
<given-names>MF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function</article-title>
<source/>Cell
          <year>2003</year>
<volume>112</volume>
<fpage>257</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(03)00035-7</pub-id>
<pub-id pub-id-type="pmid">12553913</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence</article-title>
<source/>Mol. Psychiatr.
          <year>2005</year>
<volume>10</volume>
<fpage>40</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001558</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefansson</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuregulin 1 and susceptibility to schizophrenia</article-title>
<source/>Am. J. Hum. Genet.
          <year>2002</year>
<volume>71</volume>
<fpage>877</fpage>
<lpage>892</lpage>
<pub-id pub-id-type="doi">10.1086/342734</pub-id>
<pub-id pub-id-type="pmid">12145742</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hennah</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Porteous</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The DISC1 pathway modulates expression of neurodevelopmental, synaptogenic and sensory perception genes</article-title>
<source/>PLoS. ONE.
          <year>2009</year>
<volume>4</volume>
<fpage>e4906</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0004906</pub-id>
<pub-id pub-id-type="pmid">19300510</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakata</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms</article-title>
<source/>Proc. Nat. Acad. Sci. USA
          <year>2009</year>
<volume>106</volume>
<fpage>15873</fpage>
<lpage>15878</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0903413106</pub-id>
<pub-id pub-id-type="pmid">19805229</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blum</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>The GABAergic system in schizophrenia</article-title>
<source/>Int. J. Neuropsychopharmacol.
          <year>2002</year>
<volume>5</volume>
<fpage>159</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145702002894</pub-id>
<pub-id pub-id-type="pmid">12135541</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Straub</surname>
<given-names>RE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression</article-title>
<source/>Mol. Psychiatr.
          <year>2007</year>
<volume>12</volume>
<fpage>854</fpage>
<lpage>869</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001988</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chumakov</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia</article-title>
<source/>Proc. Nat. Acad. Sci. USA
          <year>2002</year>
<volume>99</volume>
<fpage>13675</fpage>
<lpage>13680</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.182412499</pub-id>
<pub-id pub-id-type="pmid">12364586</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kvajo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dhilla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Swor</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Karayiorgou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gogos</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function</article-title>
<source/>Mol. Psychiatr.
          <year>2008</year>
<volume>13</volume>
<fpage>685</fpage>
<lpage>696</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4002052</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castillo</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Younts</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Chavez</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Hashimotodani</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Endocannabinoid signaling and synaptic function</article-title>
<source/>Neuron
          <year>2012</year>
<volume>76</volume>
<fpage>70</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.09.020</pub-id>
<pub-id pub-id-type="pmid">23040807</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parsons</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Hurd</surname>
<given-names>YL</given-names>
</name>
</person-group>
<article-title>Endocannabinoid signalling in reward and addiction</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2015</year>
<volume>16</volume>
<fpage>579</fpage>
<lpage>594</lpage>
<pub-id pub-id-type="doi">10.1038/nrn4004</pub-id>
<pub-id pub-id-type="pmid">26373473</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain</article-title>
<source/>Am. J. Hum. Genet.
          <year>2004</year>
<volume>75</volume>
<fpage>807</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1086/425589</pub-id>
<pub-id pub-id-type="pmid">15457404</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>